Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for Therapists to Enhance Psychotherapy
NCT06332066Phase 1Not yet recruiting
- Sponsor
- Shalvata Mental Health Center
- Start
- May 2024
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in Mental Disorders (MD) (2 arms), sponsored by Shalvata Mental Health Center. Primary endpoint: Patient's Experience of Attunement and Responsiveness Scale at 3 weeks. Planned start May 2024; status: not yet recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
Mental Disorders (MD)
Beyond the preview
Go deeper on NCT06332066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332066.